SCHEMBL10042945

SCHEMBL10042945

COc1ccc(C2COc3cc(C)ccc3C2(O)c2ccc(OC)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 4/20 0.42
ALOX15 P16050 3/20 0.42
MAOB P27338 1/20 0.40
KCNH2 Q12809 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
CYP19A1 P11511 4/20 0.38
CHRNA1 P02708 1/20 0.36
CHRNG P07510 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRND Q07001 1/20 0.36
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12052438 0.99 ALOX12 (0.41) ALOX12ALOX15MAOBKCNH2TRPV1
SCHEMBL2570841 0.91 ALOX15 (0.44) ALOX12ALOX15MAOBKCNH2TRPV1
SCHEMBL10042940 0.90 MEN1 (0.41) ALOX12ALOX15MAOBKCNH2TRPV1
SCHEMBL13673348 0.90 CYP19A1 (0.38) ALOX12ALOX15MAOBCYP19A1CHRNA1
SCHEMBL2570060 0.87 ALOX15 (0.44) ALOX12ALOX15MAOBKCNH2TRPV1
SCHEMBL2570756 0.82 MEN1 (0.47) ALOX12ALOX15CYP19A1CHRNA1CHRNG
SCHEMBL240709 0.82 ALOX15 (0.37) ALOX12ALOX15KCNH2TRPV1CYP19A1
SCHEMBL2571217 0.81 ESR1 (0.46) ALOX12ALOX15CYP19A1MAPTMEN1
SCHEMBL13673328 0.81 GAA (0.38) ALOX12ALOX15KCNH2TRPV1CYP19A1
SCHEMBL10042943 0.79 GAA (0.39) ALOX12ALOX15MAOBKCNH2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160287555-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY NOVOGEN RESEARCH PTY LTD (AU) 2016-10-06 US disclosed
US-9381186-B2 Substituted chroman derivatives, medicaments and use in therapy MEI PHARMA, INC. (US) 2016-07-05 US disclosed
US-20150352074-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY NOVOGEN RESEARCH PTY LTD (AU) 2015-12-10 US disclosed
US-9138478-B2 Substituted chroman derivatives, medicaments and use in therapy MEI PHARMA, INC. (US) 2015-09-22 US disclosed
US-20140170243-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY MEI PHARMA, INC. (US) 2014-06-19 US disclosed
US-20120114766-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY MARSHALL EDWARDS, INC. (US) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352074-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 ALOX12 4177/4885ALOX15 4170/4885MAOB 2322/4885
US-20140170243-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 ALOX12 4177/4885ALOX15 4170/4885MAOB 2322/4885
US-20120114766-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 ALOX12 4177/4885ALOX15 4170/4885MAOB 2322/4885
US-20160287555-A1 SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY CDYL, XPA, TP53 ALOX12 4177/4885ALOX15 4170/4885MAOB 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.